Neoadjuvant immunotherapy has the potential to enhance clinical outcomes by increasing
anti-tumor immune responses in the presence of abundant tumor-derived antigen in an …

Most head and neck cancers are squamous cell carcinomas that develop in the upper
aerodigestive epithelium after exposure to carcinogens such as tobacco and alcohol …

Treatment is complex for patients with head and neck (H&N) cancers with specific site of
disease, stage, and pathologic findings guiding treatment decision-making. Treatment …

Abstract Background and purpose The Meta-Analysis of Chemotherapy in squamous cell
Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) …

PURPOSE The standard treatment for postoperative high-risk locally advanced squamous
cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly …

Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain
limited. This raises the possibility that standard of care treatments delivered in concert may …

PURPOSE The aim of the current work is to provide evidence-based recommendations to
practicing physicians and others on the management of the neck in patients with squamous …

Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …

Background We compared concomitant cisplatin and irradiation with radiotherapy alone as
adjuvant treatment for stage III or IV head and neck cancer. Methods After undergoing …

PURPOSE To provide evidence-based recommendations to practicing physicians and other
health care providers on the diagnosis and management of squamous cell carcinoma of …